Lisata’s Marea Therapeutics doses first patient in Phase 2 MAR002 acromegaly trial
Lisata Therapeutics’ subsidiary Marea Therapeutics administered the inaugural dose of MAR002 in a Phase 2 study for acromegaly on 5 Oct 2026. The trial will enroll about 72 participants across three dose arms after a 900 mg loading dose and will assess IGF‑1 reduction after 10 weeks. MAR002 is an allosteric monoclonal antibody that could allow dosing as infrequently as once every two weeks, compared with daily injections of current therapy.
Why it matters
InvestingPro notes that each clinical milestone for MAR002 may move Lisata’s valuation, as investors watch the trial’s safety and efficacy read‑outs. The outcome will determine whether the drug can offer a more convenient treatment option for the roughly 30,000 U.S. acromegaly patients.
Key facts
- 1The Phase 2 trial plans to enroll approximately 72 participants. proactiveinvestors.com
- 2Participants will receive an initial 900 mg loading dose of MAR002. globenewswire.com
- 3The primary endpoint is IGF‑1 reduction after 10 weeks of treatment. proactiveinvestors.com
- 4MAR002 may enable dosing as infrequently as once every two weeks. globenewswire.com
- 5The first patient was dosed on 5 Oct 2026. proactiveinvestors.com
- 6Josh Lehrer, COO of Lisata and CEO of Marea, said the dosing represents an important milestone. proactiveinvestors.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.